3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
4
CNS
4
Sarcoma
1
Gynecologic
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Colonic Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Paclitaxel
575
Carboplatin
520
Cisplatin
347
Bevacizumab
252
pembrolizumab
226
Gemcitabine
157
Topotecan
128
liposomal doxorubicin
127
Cyclophosphamide
126
olaparib
120
Taxes
113
Radiotherapy
110
Docetaxel
94
Brachytherapy
89
Doxorubicin
84
Drug Therapy
80
niraparib
75
Nivolumab
71
Magnetic Resonance Spectroscopy
71
Specimen Handling
65
fludarabine
56
Biopsy
55
Hyperthermic Intraperitoneal Chemotherapy
53
Filgrastim
52
Letrozole
50
Oxaliplatin
48
durvalumab
47
Immunoglobulin G
47
atezolizumab
46
Platinum
44
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Mebendazole
×
Gynecologic
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn